SCHEMBL4032358

SCHEMBL4032358

COc1ccc(C(=O)c2cccc(Cl)c2F)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
ACHE P22303 1/20 0.48
KMT2A Q03164 2/20 0.47
KCNQ3 O43525 1/20 0.44
KCNQ2 O43526 1/20 0.44
MAPT P10636 4/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032231 0.90 NPC1 (0.50) RAB9AHTTLMNACES2CES1
SCHEMBL8180127 0.87 HTT (0.58) RAB9AHTTLMNAMAPK1CES2
SCHEMBL1407588 0.80 KMT2A (0.72) RAB9AHTTLMNAMAPK1CYP11B1
SCHEMBL8181917 0.80 HTT (0.59) RAB9AHTTLMNAMAPK1CES2
SCHEMBL1443452 0.79 LMNA (0.67) RAB9AHTTLMNAMAPK1CYP11B1
SCHEMBL28217099 0.79 HTT (0.76) RAB9AHTTLMNAMAPK1CYP11B1
SCHEMBL8050011 0.78 HTT (0.65) RAB9AHTTLMNAMAPK1CYP11B1
SCHEMBL28949182 0.77 LMNA (0.52) RAB9AHTTLMNAMAPK1CES2
SCHEMBL29816925 0.77 LMNA (0.52) RAB9AHTTLMNAMAPK1CES2
SCHEMBL1407465 0.77 CYP1A2 (0.45) RAB9AHTTLMNAMAPK1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
EP-1542976-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES Wyeth (US) 2005-06-22 EP disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed
WO-2004031159-A1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH (US) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR RAB9A 321/4885HTT 3575/4885LMNA 4029/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 RAB9A 930/4885HTT 3868/4885LMNA 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.